Treatment targeting the PD-1/PD-L1 pathway has demonstrated improvements in response and survival in phase II and phase III clinical trials in oncology including treatment for cervical cancer, lung cancer, and melanoma (Colombo et al., 2021, Mok et al., 2019, Robert et al., 2015, Kwok et al., 2016). This evidence concerns the gene CD274 and lung cancer.